Novel antitrypansomal agents

Expert Opinion on Investigational Drugs

Volumn 14, Issue 8, 2005, Pages 939-955

  Steverding, Dietmar ^a   Tyler, Kevin M ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Anti trypanosomal agents; Anti tubulin agents; Chaga's disease; Cysteine protease inhibitors; DNA topoisomerase inhibitors; Proteasome inhibitors; Sleeping sickness; Sterol biosynthesis inhiitors; Trypanosoma brucei; Trypanosoma cruzi

Indexed keywords

ANTHRACYCLINE; ANTIPROTOZOAL AGENT; ANTITRYPANOSOMAL AGENT; BISPHOSPHONIC ACID DERIVATIVE; BORONIC ACID DERIVATIVE; CAMPTOTHECIN DERIVATIVE; CYSTEINE PROTEINASE; DAUNORUBICIN; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; EPOXOMICIN; HYDRAZIDE DERIVATIVE; IRINOTECAN; LANOSTEROL DERIVATIVE; LANOSTEROL SYNTHASE; LIPID; LYSOPHOSPHOLIPID; MITOXANTRONE; PROTEASOME INHIBITOR; PROTEINASE INHIBITOR; PYRROLE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SQUALENE SYNTHASE INHIBITOR; THIOSEMICARBAZONE DERIVATIVE; THIOUREA DERIVATIVE; TOPOTECAN; TRIFLURALIN; TUBULIN; UNINDEXED DRUG; UREA DERIVATIVE; NEW DRUG;

AFRICAN TRYPANOSOMIASIS; ANTIBIOTIC RESISTANCE; ANTIPROTOZOAL ACTIVITY; CHAGAS DISEASE; CHEMOTHERAPY; CLINICAL TRIAL; DISEASE MODEL; DRUG EFFICACY; DRUG STRUCTURE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LIPOGENESIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PARASITEMIA; REVIEW; STRUCTURE ACTIVITY RELATION; TRYPANOSOMA; TRYPANOSOMIASIS; ANIMAL; CHEMISTRY; METABOLISM;

ANIMALS; CHAGAS DISEASE; DRUGS, INVESTIGATIONAL; HUMANS; TRYPANOCIDAL AGENTS; TRYPANOSOMIASIS, AFRICAN;

EID: 23644451667     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.8.939     Document Type: Review

References (146)

1. BARRETT MP, BURCHMORE RJ, STICH A et al.: The trypanosomiases. Lancet (2003) 362(9394):1469-1480.
2. WHO: African trypanosomiasis or sleeping sickness. World Health Org. Fact Sheet (2001) 259. http://www.who.int/mediacentre/factsheets/fs259/en/
3. WILLIAMS-BLANGERO S, VANDEBERG JL, BLANGERO J, CORRÊA-OLIVEIRA R: Genetic epidemiology of Trypanosoma cruzi infection and Chagas' disease. Front. Biosci. (2003) 8:e337-e345.
4. MOLYNEUX DH: Current public health status of the trypanosomiases and leishmaniases. In: Trypanosomiasis and Leishmaniasis: Biology and Control. Hide G, Mottram JC, Coombs GH, Holmes PH (Eds), CAB International, Wallingford, Oxon, UK (1997):39-50.
5. FAIRLAMB AH: Chemotherapy of human African trypanosomiasis: current and future prospects. Trends Parasitol. (2003) 19(11):488-494.
6. URBINA JA, DOCAMPO R: Specific chemotherapy of Chagas disease: controversies and advances. Trends Parasitol. (2003) 19(1):495-501.
7. COURA JR, DE CASTRO SL: A critical review on Chagas disease chemotherapy. Mem. Inst. Oswaldo Cruz (2002) 97(1):3-24.
8. JANNIN J, CATTAND P: Treatment and control of human African trypanosomiasis. Curr. Opin. Infect. Dis. (2004) 17(6):564-571.
9. WICKWARE P: Resurrecting the resurrection drug. Nat. Med. (2002) 8(9):908-909.
10. CAFFREY CR, SCORY S, STEVERDING D: Cysteine proteinases of trypanosome parasites: novel targets for chemotherapy. Curr. Drug Targets (2000) 1(2):155-162.
11. NASCIMENTO AE, DE SOUZA W: High resolution localization of cruzipain and Ssp4 in Trypanosoma cruzi by replica staining label fracture. Biol. Cell (1996) 86(1):53-58.
12. HUETE-PÉREZ JA, ENGEL JC, BRINEN LS, MOTTRAM JC, McKERROW JH: Protease trafficking in two primitive eukaryotes is mediated by a prodomain protein motif. J. Biol. Chem. (1999) 274(23):16249-16256.
13. LONSDALE-ECCLES JD, GRAB DJ: Lysosomal and non-lysosomal peptidyl hydrolases of the bloodstream forms of Trypanosoma brucei brucei. Eur. J. Biochem. (1987) 169(3):467-475.
14. CAFFREY CR, HANSELL E, LUCAS KD et al.: Active site mapping, biochemical properties and subcellular localization of rhodesain, the major cysteine protease of Trypanosoma brucei rhodesiense. Mol. Biochem. Parasitol. (2001) 118(1):61-73.
15. ASHALL F, ANGLIKER H, SHAW E: Lysis of trypanosomes by peptidyl fluoromethyl ketones. Biochem. Biophys. Res. Commun. (1990) 170(2):923-929.
16. OTTO H-H, SCHIRMEISTER T: Cysteine proteases and their inhibitors. Chem. Rev. (1997) 97(1):133-172.
17. TROEBERG L, MORTY RE, PIKE RH et al.: Cysteine proteinase inhibitors kill cultured bloodstream forms of Trypanosoma brucei brucei. Exp. Parasitol. (1999) 91(4):349-355.
18. 2. Exp. Parasitol. (1999) 91(4):327-333.
19. PALMER JT, RASNICK D, KLAUS JL, BRÖMME D: Vinyl sulfones as mechanism-based cysteine protease inhibitors. J. Med. Chem. (1995) 38(17):3193-3196.
20. ENGEL JC, DOYLE PS, PALMER J, HSIEH I, BAINTON DF, McKERROW JH: Cysteine protease inhibitors alter Golgi complex ultrastructure and function in Trypanosoma cruzi. J. Cell Sci. (1998) 111(5):597-606.
21. ENGEL JC, DOYLE PS, HSIEH I, McKERROW JH: Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection. J. Exp. Med. (1998) 188(4):725-734.
22. ROUSH WR, CHENG J, KNAPP-REED B et al.: Potent second generation vinyl sulfonamide inhibitors of the trypanosomal cysteine protease cruzain. Bioorg. Med. Chem. Lett. (2001) 11(20):2759-2762.
23. TROEBERG L, CHEN X, FLAHERTY TM et al.: Chalcone, acyl hydrazide, and related amides kill cultured Trypanosoma brucei brucei. Mol. Med. (2000) 6(8):660-669.
24. CAFFREY CR, SCHANZ M, NKEMGU-NJINKENG J et al.: Screening of acyl hydrazide proteinase inhibitors for antiparasitic activity against Trypanosoma brucei. Int. J. Antimicrob. Agents (2002) 19(3):227-231.
25. DU X, HANSELL E, ENGEL JC, CAFFREY CR, COHEN FE, McKERROW JH: Aryl ureas represent a new class of antitrypanosomal agents. Chem. Biol. (2000) 7(9):733-742.
26. DU X, GUO C, HANSELL E et al.: Synthesis and structure-activity relationship study of potent trypanocidal thio semicarbazone inhibitors of the trypanosomal cysteine protease cruzain. J. Med. Chem. (2002) 45(13):2695-2707.
27. GREENBAUM DC, MACKEY Z, HANSELL E et al.: Synthesis and structure-activity relationships of parasiticidal thiosemicarbazone cysteine protease inhibitors against Plasmodium falciparum, Trypanosoma brucei, and Trypanosoma cruzi. J. Med. Chem. (2004) 47(12):3212-3219.
28. COUX O, TANAKA K, GOLDBERG AL: Structure and functions of the 20S and 26S proteasome. Ann. Rev. Biochem. (1996) 65:801-847.
29. LI Z, ZOU C-B, YAO Y et al.: An easily dissociated 26 S proteasome catalyzes an essential ubiquitin-mediated protein degradation pathway in Trypanosoma brucei. J. Biol. Chem. (2002) 277(18):15486-15498.
30. HUA S-B, TO W-Y, NGUYEN TT, WONG M-L, WANG CC: Purification and characterization of proteasomes from Trypanosoma brucei. Mol. Biochem. Parasitol. (1996) 78(1-2):33-46.
31. WANG CC, BOZDECH Z, LIU C-L et al.: Biochemical analysis of the 20 S proteasome of Trypanosoma brucei. J. Biol. Chem. (2003) 278(18):15800-15808.
32. KISSELEV AF, GOLDBERG AL: Proteasome inhibitors: from research tools to drug candidates. Chem. Biol. (2001) 8(8):739-758.
33. NKEMGU-NJINKENG J, ROSENKRANZ V, WINK M, STEVERDING D: Antitrypanosomal activities of proteasome inhibitors. Antimicrob. Agents Chemother. (2002) 46(6):2038-2040.
34. BOGYO M, McMASTER JS, GACZYNSKA M, TORTORELLA D, GOLDBERG AL, PLOEGH H: Covalent modification of the active site threonine of proteasomal β subunits and the Escherichia coli homolog HsIV by a new class of inhibitors. Proc. Natl. Acad. Sci. USA (1997) 94(13):6629-6634.
35. BOGYO M, SHIN S, McMASTER JS, PLEOGH HL: Substrate binding and sequence preference of the proteasome revealed by active-site-directed affinity probes. Chem. Biol. (1998) 5(6):307-320.
36. STEVERDING D, SPACKMAN RW, ROYLE HJ, GLENN RJ: Trypanocidal activities of trileucine methyl vinyl sulfone proteasome inhibitors. Parasitol. Res. (2005) 95(1):73-76.
37. KESSLER BM, TORTORELLA D, ALTUN M et al.: Extended peptide-based inhibitors efficiently target the proteasome and reveal overlapping specificities of the catalytic β-subunits. Chem. Biol. (2001) 8(9):913-929.
38. GLENN RJ, PEMBERTON AJ, ROYLE HJ et al.: Trypanocidal effect of α′,β′-epoxyketones indicates that trypanosomes are particularly sensitive to inhibitors of proteasome trypsin-like activity. Int. J. Antimicrob. Agents (2004) 24(3):286-289.
39. GROLL M, KIM KB, KAIRIES N, HUBER R, CREWS CM: Crystal structures of epoxomicin:20S proteasome reveals a molecular basis for selectivity of α′,β′-epoxyketone proteasome inhibitors. J. Am. Chem. Soc. (2000) 122(6):1237-1238.
40. MERSCHJOAHNN K, SPORER F, STEVERDING D, WINK M: In vitro effect of alkaloids on bloodstream forms of Trypanosoma brucei and T. congolense. Planta Med. (2001) 67(7):623-627.
41. ADAMS J, BEHNKE M, CHEN S et al.: Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg. Med. Chem. Lett. (1998) 8(4):333-338.
42. NKEMGU-NJINKENG J: Studies on the trypanocidal activities of cysteine proteinase and proteasome inhibitors. MD Thesis, University of Heidelberg, Germany (2002).
43. NITISS JL: Investigating the biological function of DNA topoisomerases in eukaryotic cells. Biochim. Biophys. Acta (1998) 1400(1-3):63-81.
44. STEWART L, REDINBO MR, QUI X, HOL WGJ, CHAMPOUX JJ: A model for the mechanism of human topoisomerase I. Science (1998) 279(5356)1534-1541.
45. BERGER JM, GAMBLIN SJ, HARRISON SC, WANG JC: Structure and mechanism of DNA topoisomerase II. Nature (1996) 379(6562):225-232.
46. DAS A, DASGUPTA A, SENGUPTA T, MAJUMDER HK: Topoisomerases of kinetoplastid parasites as potential chemotherapeutic targets. Trends Parasitol. (2004) 20(8):381-387.
47. BODLEY AL, CHAKRABORTY AK, XIE S, BURRI C, SHAPIRO TA: An unusual type IB topoisomerase from African trypanosomes. Proc. Natl. Acad. Sci. USA (2003) 100(13):7539-7544.
48. BAKSHI RP, SHAPIRO TA: RNA interference of Trypanosoma brucei topoisomerase IB: both subunits are essential. Mol. Biochem. Parasitol. (2004) 136(2):249-255.
49. WANG Z, ENGLUND PT: RNA interference of a trypanosome topoisomerase II causes progressive loss of mitochondrial DNA. EMBO J. (2001) 20(17):4674-4683.
50. TOPCU Z: DNA topoisomerases as targets for anticancer drugs. J. Clin. Pharm. Ther. (2001) 26(6):405-416.
51. BODLEY AL, WANI MC, WALL ME, SHAPIRO TA: Antitrypanosomal activity of camptothecin analogs. Structure-activity correlations. Biochem. Pharmacol. (1995) 50(7):937-942.
52. DETERRING A, DUNGEY FA, THOMPSON K-T, STEVERDING D: Anti-trypanosomal activities of DNA topoisomerase inhibitors. Acta Trop. (2005) 93(3):311-316.
53. SLATTER JG, SU P, SAMS JP, SCHAAF LJ, WIENKERS LC: Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Drug Metab. Dispos. (1997) 25(10):1157-1164.
54. WILLIAMSON J, SCOTT-FINNIGAN TJ: Trypanocidal activity of antitumour antibiotics and other metabolic inhibitors. Antimicrob. Agents Chemother. (1978) 13(5):735-744.
55. NENORTAS E, BURRI C, SHAPIRO TA: Antitrypanosomal activity of fluoroquinolones. Antimicrob. Agents Chemother. (1999) 43(8):2066-2068.
56. KEISER J, BURRI C: Evaluation of quinolone derivatives for antitrypanosomal activity. Trop. Med. Int. Health (2001) 6(5):369-389.
57. NENORTAS E, KULIKOWICZ T, BURRI C, SHAPIRO TA: Antitrypanosomal activities of fluoroquinolones with pyrrolidinyl substitutions. Antimicrob. Agents Chemother. (2003) 47(9):3015-3017.
58. SCHELD WM: Quinolone therapy for infections of the central nervous system. Rev. Infect. Dis. (1989) 11(Suppl. 5):S1194-S1202.
59. GULL K: The cytoskeleton of trypanosomatid parasites. Ann. Rev. Microbiol. (1999) 53:629-655.
60. VAUGHAN S, ATTWOOD T, NAVARRO M, SCOTT V, McKEAN P, GULL K: New tubulins in protozoal parasites. Curr. Biol. (2000) 10(7):R258-R259.
61. GULL K: Protist tubulins: new arrivals, evolutionay relationships and insights to cytoskeletal function. Curr. Opin. Microbiol. (2001) 4(4):427-432.
62. GULL K: Antimicrotubule agents. In: Report of a Meeting on the Development of Drugs against Trypanosomiasis, Leishmaniasis and Chagas Disease. TDR/TRY/DRUG/90.4, WHO, Geneva, Switzerland (1990):2-13.
63. BAUM SG, WITTNER M, NADLER JP et al.: Taxol, a microtubule stabilizing agent, blocks the replication of Trypanosoma cruzi. Proc. Natl. Acad. Sci. USA (1981) 78(7):4571-4575.
64. OCHOLA DO, PRICHARD PK, LUBEGA GW: Classical ligands bind tubulin of trypanosomes and inhibit their growth in vitro. J. Parasitol. (2002) 88(3):600-604.
65. ROBINSON DR, SHERWIN T, PLOUBIDOU A, BYARD EH, GULL K: Microtubule polarity and dynamics in the control of organelle positioning, segregation, and cytokinesis in the trypanosome cell cycle. J. Cell Biol. (1995) 128(6):1163-1172.
66. TRAUB-CSEKO YM, RAMALHO-ORTIGÃO JM, DANTAS AP, DE CASTRO SL, BARBOSA HS, DOWNING KH: Dinitroaniline herbicides against protozoan parasites: the case of Trypanosoma cruzi. Trends Parasitol. (2001) 17(3):136-141.
67. ZAIDENBERG A, TOURNIER H, SCHINELLA G, MARIN G, BUSCHIAZZO H: Effects of trifluralin on Trypanosoma cruzi in vitro and in vivo. Pharmacol. Toxicol. (1999) 84(2):98-100.
68. WERBOVETZ KA, SACKETT DL, DELFÍN D et al.: Selective antimicrotuble activity of N1-phenyl-3,5-dinitro-N4,N4-di-n-propylsulfanilamide (GB-II-5) against kinetoplastid parasites. Mol. Pharmacol. (2003) 64(6):1325-1333.
69. 4-substituted 3,4-dinitro sulfanilamides against African trypanosomes and Leishmania. J. Med. Chem. (2004) 47(7):1823-1832.
70. DIXON H, GINGER CD, WILLIAMSON J: Trypanosome sterols and their metabolic origins. Comp. Biochem. Phyiol. B (1972) 41(1):1-18.
71. ROBERTS CW, McLEOD R, RICE DW, GINGER M, CHANCE KL, GOAD LJ: Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa. Mol. Biochem. Parasitol. (2003) 126(2):129-142.
72. LIRA R, CONTRERAS LM, SANTA RITA RM, URBINA JA: Mechanism of action of anti-proliferative lysophospholipid analogues against the protozoan parasite Trypanosoma cruzi: potentiation of in vitro activity by the sterol biosynthesis inhibitor ketoconazole. J. Antimicrob. Chemother. (2001) 47(5):537-546.
73. COPPENS I, LEVADE T, COURTOY PJ: Host plasma low density lipoprotein particles as an essential source of lipids for the bloodstream forms of Trypanosoma brucei. J. Biol. Chem. (1995) 270(11):5736-5741.
74. COPPENS I, BAUDHUIN P, OPPERDOES FR, COURTOY PJ: Receptors for the host low density lipoproteins on the hemoflagellate Trypanosoma brucei: purification and involvement in the growth of the parasite. Proc. Natl. Acad. Sci. USA (1988) 85(18):6753-6757.
75. CHARBONNEAU C, FOURNIER I, DUFRESNE S, BARWICZ J, TANCREDE P: The interactions of amphotericin B with various sterols in relation to its possible use in anticancer therapy. Biophys. Chem. (2001) 91(2):125-133.
76. YARDLEY V, CROFT SL: In vitro and in vivo activity of amphotericin B-lipid formulations against experimental Trypanosoma cruzi infections. Am. J. Trop. Med. Hyg. (1999) 61(2):193-197.
77. SANTA-RITA RM, SANTOS BARBOSA H, MEIRELLES MNSL, DE CASTRO SL: Effect of the alkyllysophospholipids on the proliferation and differentiation of Trypanosoma cruzi. Acta Trop. (2000) 75(2):219-228.
78. WALD NJ, LAW MR: A strategy to reduce cardiovascular disease by more than 80%. Br. Med. J. (2003) 326(7404):1419.
79. FLORIN-CHRISTENSEN M, FLORIN-CHRISTENSEN J, GARIN C, ISOLA E, BRENNER RR, RASMUSSEN L: Inhibition of Trypanosoma cruzi growth and sterol biosynthesis by lovastatin. Biochem. Biophys. Res. Commun. (1990) 166(3):1441-1445.
80. URBINA JA, LAZARDI K, MARCHAN E et al.: Mevinolin (lovastatin) potentiates the antiproliferative effect of ketoconazole and terbinafine against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Antimicrob. Agents Chemother. (1993) 37(3):580-591.
81. HURTADO-GUERRERO R, PEÑA-DÍAZ J, MONTALVETTI A, RUIZ-PÉREZ LM, GONZÁLEZ-PACANOWSKA D: Kinetic properties and inhibition of Trypanosoma cruzi 3-hydroxy-3-methylglutaryl CoA reductase. FEBS Lett. (2002) 510(3):141-144.
82. PEÑA-DÍAZ J, MONTALVETTI A, FLORES CL et al.: Mitochondrial localization of the mevalonate pathway enzyme 3-hydroxy-3-methyl-glutaryl-CoA reductase in the Trypanosomatidae. Mol. Biol. Cell (2004) 15(3):1356-1363.
83. MONTALVETTI A, BAILEY BN, MARTIN MB, SEVERIN GW, OLDFIELD E, DOCAMPO R: Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase. J. Biol. Chem. (2001) 276(36):33930-33937.
84. MARTIN MB, GRIMLEY JS, LEWIS JC et al.: Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy. J. Med. Chem. (2001) 44(6):909-916.
85. URBINA JA, MORENO B, VIERKOTTER S et al.: Trypanosoma cruzi contains major pyrophosphate stores, and its growth in vitro and in vivo is blocked by pyrophosphate analogs. J. Biol. Chem. (1999) 274(47):33609-33615.
86. GARZONI LR, CALDERA A, MEIRELLES MNL et al.: Selective in vitro effects of the farnesyl pyrophosphate synthase inhibitor risedronate on Trypanosoma cruzi. Int. J. Antimicrob. Agents (2004) 23(3):273-285.
87. GARZONI LR, WAGHABI MC, BAPTISTA MM et al.: Antiparasitic activity of risedronate in a murine model of acute Chagas' disease. Int. J. Antimicrob. Agents (2004) 23(3):286-290.
88. RODAN GA, MARTIN TJ: Therapeutic approaches to bone diseases. Science (2000) 289(5484):1508-1514.
89. URBINA JA, CONCEPCION JL, RANGEL S, VISBAL G, LIRA R: Squalene synthase as a chemotherapeutic target in Trypanosoma cruzi and Leishmania mexicana. Mol. Biochem. Parasitol. (2002) 125(1-2):35-45.
90. ORENES LORENTE S, GÓMEZ R, JIMÉMEZ C et al.: Biphenylquinuclidines as inhibitors of squalen synthase and growth of parasitic protozoa. Bioorg. Med. Chem. (2005) 13(10): 3519-3529.
91. URBINA JA, CONCEPCION JL, CLADERA A et al.: In vitro and in vivo activities of E5700 and ER-119884, two novel orally-active squalene synthase inhibitors, against Trypanosoma cruzi. Antimicrob. Agents Chemother. (2004) 48(7):2379-2387.
92. URBINA JA, CONCEPCION JL, MONTALVETTI A, RODRIGUEZ JB, DOCAMPO R: Mechanism of action of 4-phenoxyphenoxyethyl thiocyanate (WC-9) against Trypanosoma cruzi, the causative agent of Chagas' disease. Antimicrob. Agents Chemother. (2003) 47(6):2047-2050.
93. URBINA JA, LAZARDI K, AGUIRRE T, PIRAS MM, PIRAS R: Antiproliferative synergism of the allylamine SF-86-327 and ketoconazole on epimastogotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. Antimicrob. Agents Chemother. (1988) 32(8):1237-1242.
94. DE CONTI R, RITA RM, DE SOUZA EM et al.: In vitro trypanocidal activities of a novel series of N,N-dimethyl-2-propen-1-amine derivative. Microbes (1996) 85(343):83-87.
95. DE SOUZA AO, HEMERLY FP, BUSOLLO AC et al.: 3-[4′-Bromo-(1,1′biphenyl)-4-yl]-N,N- dimethyl-3-(2-thienyl)-2-propen-1-amine: synthesis, cytotoxicity, and leishmanicidal, trypanocidal and antimycobacterial activities. J. Antimicrob. Chemother. (2002) 50(5):629-637.
96. DE SOUZA AO, HEMERLY FP, GOMES-CARDOSO L et al.: 2-Propen-1-amine derivatives and their synthetic intermediates: activity against pathogenic trypanosomatids. J. Chemother. (2004) 16(6):530-533.
97. OLIVEIRA DA, PEREIRA DG, FERNANDES AMAP et al.: Trypanocidal activity of 2-propen-1-amine derivatives on trypomastigotes culture and in animal model. Parasitol. Res. (2005) 95(3):161-166.
98. BUCKNER FS, GRIFFEN JH, WILSON AJ, VAN VOORHIS WC: Potent anti-Trypanosoma cruzi activities of oxidosqualene cyclase inhibitors. Antimicrob. Agents Chemother. (2001) 45(4):1210-1215.
99. FROMTLING RA: Overview of medically importmant antifungal azole derivatives. Clin. Microbiol. Rev. (1988) 1(2):187-217.
100. McCABE RE, ARAUJO FG, REMINGTON JS: Ketoconazole protects against infection with Trypanosoma cruzi in a murine model. Am. J. Trop. Hyg. (1983) 32(5):960-962.
101. McCABE RE, REMINGTON JS, ARAUJO FG: Ketoconazole inhibition of intracellular multiplication of Trypanosoma cruzi and protection of mice against lethal infection with the organism. J. Infect. Dis. (1984) 150(4):594-601.
102. ARAÚJO MSS, MARTINS-FILHO OA, PEREIRA MES, BRENER Z: A combination of benznidazole and ketoconazole enhances efficacy of chemotherapy of experimental Chagas' disease. J. Antimicrob. Chemother. (2000) 45(6):819-824.
103. BRENER Z, CANCADO JR, GALVAO LM et al.: An experimental and clinical assay with ketoconazole in the treatment of Chagas disease. Mem. Inst. Oswaldo Cruz (1993) 88(1):149-153.
104. APT W, AGUILERA X, ARRIBADA A et al.: Treatment of chronic Chagas' disease with itraconazole and allopurinol. Am. J. Trop. Med. Hyg. (1998) 59(1):133-138.
105. BUCKNER FS, WILSON AJ, WHITE TC, VAN VOORHIS WC: Induction of resistance to azole drugs in Trypanosoma cruzi. Antimicrob. Agents Chemother. (1998) 42(12):3245-3250.
106. URBINA JA, PAYARES G, MOLINA J et al.: Cure of short- and long-term experimental Chagas' disease using D0870. Science (1996) 273(5277):969-971.
107. WILLIAMS KJ, DENNING DW: Termination of development of D0870. J. Antimicrob. Chemother. (2001) 47(5):700-701.
108. MOLINA J, MARTINS-FILHO O, BRENER Z, ROMANHA AJ, LOEBENBERG D, URBINA JA: Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts. Antimicrob. Agents Chemother. (2000) 44(1):150-155.
109. URBINA JA, LIRA R, VISBAL G, BARTROLI J: In vitro antiproliferative effects and mechanism of action of the new triazole derivative UR-9825 against the protozoan parasite Trypanosoma (Schizotrypanum) cruzi. Antimicrob. Agents Chemother. (2000) 44(9):2498-2502.
110. GUEDES PMM, URBINA JA, DE LANA M et al.: Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts. Antimicrob. Agents Chemother. (2004) 48(11):4286-4292.
111. URBINA JA, PAYARES G, SANOJA C et al.: Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains. Int. J. Antimicrob. Agents (2003) 21(1):39-48.
112. URBINA JA, PAYARES G, SANOJA C, LIRA R, ROMAN HA AJ: In vitro and in vivo activities of ravuconazole on Typanosoma cruzi, the causative agents of Chagas disease. Int. J. Antimicrob. Agents (2003) 21(1):27-38.
113. BUCKNER F, YOKOYAMA K, LOCKMAN J et al.: A class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents. Proc. Natl. Acad. Sci. USA (2003) 100(25):15149-14153.
114. MAGARACI F, JIMENEZ CJ, RODRIGUES C et al.: Azasterols as inhibitors of sterol 24-methyltransferase in Leishmania species and Trypanosoma cruzi. J. Med. Chem. (2003) 46(22):4714-4727.
115. ORENES LORENTE S, RODRIGUEZ JCF, JIMÉNEZ CJ et al.: Novel azasterols as potential agents for treatment of leishmaniasis and trypanosomiasis. Antimicrob. Agents Chemother. (2004) 48(8):2937-2950.
116. CROFT SL, COOMBS GH: Leishmaniasis - current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol. (2003) 19(11):502-508.
117. CROFT S, SNOWDON D, YARDLEY V: The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J. Antimicrob. Chemother. (1996) 38(6):1041-1047.
118. SARAIVA VB, GIBALDI D, PREVIATO JO et al.: Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi. Antimicrob. Agents Chemother. (2002) 46(11):3472-3477.
119. SANTA-RITA RM, LIRA R, BARBOSA HS, URBINA JA, DE CASTRO SL: Antiproliferative synergy of lysophospholipid analogues and ketoconazole against Trypanosoma cruzi (Kinetoplastida: Trypanosomatidae): cellular and ultrastructural analysis. J. Antimicrob. Chemother. (2005) 55(5):780-784.
120. GELB MH, VAN VORHEIS WC, BUCKNER FS et al.: Protein farnesyl and N-myristol transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics. Mol. Biochem. Parasitol. (2003) 126(2):155-163.
121. CLERICI F, GELMI ML, YOKOYAMA K et al.: Isothiazole dioxides: synthesis and inhibition of Trypanosoma brucei protein farnesyltransferase. Bioorg. Med. Chem. Lett. (2002) 12(16):2217-2220.
122. OHKANDA J, BUCKNER FS, LOCKMAN JW et al.: Design and synthesis of peptidomimetic protein farnesyltransferase inhibitors as antiTrypanosoma brucei agents. J. Med. Chem. (2004) 47(2):432-445.
123. AGUIRRE G, CERECETTO H, DI MAIO R et al.: Quinoxaline N,N-dioxide derivatives and related compounds as growth inhibitors of Trypanosoma cruzi. Structure-activity relationships. Bioorg. Med. Chem. Lett. (2004) 14(14):3835-3839.
124. DAUNES S, D'SILVA C: Gluthathione derivatives active against Trypanosoma brucei rhodesiense and T. brucei brucei in vitro. Antimicrob. Agents Chemother. (2002) 46(2):434-437.
125. ZOU Y, WU Z, SIRISOMA N et al.: Novel alkylpolyamine analogues that posses both antitrypanosomal and antimicrosporidial activity. Bioorg. Med. Chem. Lett. (2001) 11(12):1613-1617.
126. KLENKE B, STEWART M, BARRETT MP, BRUN R, GILBERT IH: Synthesis and biological evaluation of s-triazine substituted polyamines as potential new antitrypanosomal drugs. J. Med. Chem. (2001) 44(21):3440-3452.
127. DARDONVILLE C, BRUN R: Bisguanidine, bis(2-aminoimidazoline), and polyamine derivatives as potent and selective chemotherapeutic agents against Trypanosoma brucei rhodesiense. Synthesis and in vitro evaluation. J. Med. Chem. (2004) 47(9):2296-2307.
128. MARASCO CJ JR, KRAMER DL, MILLAR J et al.: Synthesis and evaluation of analogues of 5′-([(Z)-4-amino-2- butenyl]methylamino)-5′-deoxyadenosine as inhibitor of tumor cell growth, trypanosomal growth, and HIV-1 infectivity. J. Med. Chem. (2002) 45(23):5112-5122.
129. ARZEL E, ROCCA P, GRELLIER P et al.: New synthesis of benzo-δ-carbolines, crytolepines, and their salts: in vitro cytotoxic, antiplasmodial, and antitrypanosomal activities of δ-carbolines, benzo-δ-carbolines, and cryptolepines. J. Med. Chem. (2001) 44(6):949-960.
130. KELLY JM, QUACK G, MILES MM: In vitro and in vivo activities of aminoadamantane and aminoalkylcyclohexane derivatives against Trypanosoma brucei. Antimicrob. Agents Chemother. (2001) 45(5):1360-1366.
131. AGUIRRE G, CERECETTO H, DI MAIO R et al.: Benzo[1,2-c]1,2,5-oxadiazole N-oxide derivatives as potential antitrypanosomal drugs. Structure-activity relationships. Part II. Arch. Pharm. (Weinheim) (2002) 335(1):15-21.
132. BAL G, VAN DER VEKEN P, ANTONOV D et al.: Prolylisoxazoles: potent inhibitors of prolyloligopeptidase with antitrypanosomal activity. Bioorg. Med. Chem. Lett. (2003) 13(17):2875-2878.
133. SEEBACHER W, BRUN R, WEIS R: New 4-aminobicyclo[2.2.2]octane derivatives and their activities against Plasmodium falciparum and Trypanosoma b. rhodesiense. Eur. J. Pharm. Sci. (2004) 21(2-3):225-233.
134. SEEBACHER W, SCHLAPPER C, BRUN R, KAISER M, SAF R, WEIS R: Antiprotozoal activities of new bicycle[2.2.2]octan-2-imines and esters of bicycle [2.2.2]octan-2-ols. Eur. J. Pharm. Sci. (2005) 24(4):281-289.
135. CERECETTO H, DI MAIO R, GONZÁLEZ M et al.: Synthesis and antitrypanosomal evaluation of E-isomers of 5-nitro-2-furaldehyde and 5-nitrothiophene-2-carboxaldehyde semicarbazone derivatives. Structure-activity relationships. Eur. J. Med. Chem. (2000) 35(3):343-350.
136. MILLET R, MASS L, LANDRY V, SERGHERAERT C, DAVIOUT-CHARVET E: Antitrypanosomal activities and cytotoxicity of 5-nitro-2-furancarbohydrazides. Bioorg. Med. Chem. Lett. (2002) 12(24):3601-3604.
137. CHUNG M-C, GÜIDO RVC, MARTINELLI TF et al.: Synthesis and in vitro evaluation of potential antichagasic hydroxymethylnitrofurazone (NFOH-121): a new nitofurazone prodrug. Bioorg. Med. Chem. (2003) 11(22):4779-4783.
138. STEWART M, BUENO GJ, BALIANI A et al.: Trypanocidal activity of melamine-based nitroheterocycles. Antimicrob. Agents Chemother. (2004) 48(5):1733-1738.
139. AGUIRRE G, BOIANI L, CERECETTO H et al.: In vitro activity and mechanism of action against the protozoan parasite Trypanosoma cruzi of 5-nitrofuryl containing thiosemicarbazones. Bioorg. Med. Chem. (2004) 12(18):4885-4893.
140. POZAS R, CARBALLO J, CASTRO C, RUBIO J: Synthesis and in vitro antitrypanosomal activity of novel nifurtimox analogues. Bioorg. Med. Chem. Lett. (2005) 15(5):1417-1421.
141. ISMAIL MA, BRUN R, EASTERBROOK JD, TANIOUS FA, WILSON WD, BOYKIN DW: Synthesis and antiprotozoal activity of aza-analogues of furamidine. J. Med. Chem. (2003) 46(22):4761-4769.
142. ISMAIL AM, BRUN R, WENZLER T, TANIOUS FA, WILSON WD, BOYKIN DW: Novel dicationic imidazo[1,2-a]pyridines and 5,6,7,8-tetrahydro-imidazo[1,2-a]pyridines as antiprotozoal agents. J. Med. Chem. (2004) 47(14):3658-3664.
143. ANSEDE JH, ANBAZHAGAN M, BRUN R, EASTERBROOK JD, HALL JE, BOYKIN DW: O-alkoxyamidine prodrugs of furamidine: in vitro transport and microsomal metabolism as indicators of in vivo efficacy in a mouse model of Trypanosoma brucei rhodesiense infection. J. Med. Chem. (2004) 47(17):4335-4338.
144. ISMAIL MA, BRUN R, WENZLER T, TANIOUS FA, WILSON WD, BOYKIN DW: Dicationic biphenyl benzimidazole derivatives as antiprotozoal agents. Bioorg. Med. Chem. (2004) 12(20):5405-5413.
145. HOET S, OPPERDOES F, BRUN R, QUETIN-LECLERCQJ: Natural products active against African trypanosomes: a step towards new drugs. Nat. Prod. Rep. (2004) 21(3):353-364.
146. YABU Y, YOSHIDA A, SUZUKI T et al.: The efficacy of ascufuranone in a consecutive treatment on Trypanosoma brucei brucei in mice. Parasitol. Int. (2003) 52(2):155-164.